Literature DB >> 15802822

The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain.

Hisae Hayashi1, Michihisa Tohda, Hiroshi Watanabe, Yukihisa Murakami, Kinzo Matsumoto.   

Abstract

Choto-san is a Kampo medicines that has been used clinically for the treatment of dementia. We measured the mRNA expressions of some factors related to Alzheimer's disease in a dementia model rat brain. The expressions of beta-amyloid precursor protein, gamma-secretase, alpha7 nicotinic acetylcholine receptor, neprilysin, and insulin degrading enzyme (IDE) were significantly increased on day 4 after permanent occlusion of the bilateral common carotid arteries (2VO). Choto-san inhibited the enhancement of IDE expression caused by 2VO, although it failed to show any effects on the expressions of the other molecules. These results suggest that Choto-san may produce a state in which it is not necessary to induce IDE expression to demonstrate the anti-dementia effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802822     DOI: 10.1248/bpb.28.744

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

1.  Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response.

Authors:  Toru Hiratsuka; Shinsuke Matsuzaki; Shingo Miyata; Mitsuhiro Kinoshita; Kazuaki Kakehi; Shinji Nishida; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

Review 2.  Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; Caroline Kerridge; Anthony J Turner
Journal:  Front Aging Neurosci       Date:  2014-09-17       Impact factor: 5.750

3.  Quantitative Analysis and Biological Efficacies regarding the Neuroprotective and Antineuroinflammatory Actions of the Herbal Formula Jodeungsan in HT22 Hippocampal Cells and BV-2 Microglia.

Authors:  Yu Jin Kim; Hye-Sun Lim; Bu-Yeo Kim; Chang-Seob Seo; Soo-Jin Jeong
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-17       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.